Anti-UROK/ PLAU/ ATF monoclonal antibody

Anti-UROK/ PLAU/ ATF antibody for FACS & in-vivo assay

Target products collectionGo to PLAU/PLAU products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T17758-Ab-1/ GM-Tg-hg-T17758-Ab-2Anti-Human PLAU monoclonal antibodyHuman
GM-Tg-rg-T17758-Ab-1/ GM-Tg-rg-T17758-Ab-2Anti-Rat PLAU monoclonal antibodyRat
GM-Tg-mg-T17758-Ab-1/ GM-Tg-mg-T17758-Ab-2Anti-Mouse PLAU monoclonal antibodyMouse
GM-Tg-cynog-T17758-Ab-1/ GM-Tg-cynog-T17758-Ab-2Anti-Cynomolgus/ Rhesus macaque PLAU monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T17758-Ab-1/ GM-Tg-felg-T17758-Ab-2Anti-Feline PLAU monoclonal antibodyFeline
GM-Tg-cang-T17758-Ab-1/ GM-Tg-cang-T17758-Ab-2Anti-Canine PLAU monoclonal antibodyCanine
GM-Tg-bovg-T17758-Ab-1/ GM-Tg-bovg-T17758-Ab-2Anti-Bovine PLAU monoclonal antibodyBovine
GM-Tg-equg-T17758-Ab-1/ GM-Tg-equg-T17758-Ab-2Anti-Equine PLAU monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T17758-Ab-1/ GM-Tg-hg-T17758-Ab-2; GM-Tg-rg-T17758-Ab-1/ GM-Tg-rg-T17758-Ab-2;
GM-Tg-mg-T17758-Ab-1/ GM-Tg-mg-T17758-Ab-2; GM-Tg-cynog-T17758-Ab-1/ GM-Tg-cynog-T17758-Ab-2;
GM-Tg-felg-T17758-Ab-1/ GM-Tg-felg-T17758-Ab-2; GM-Tg-cang-T17758-Ab-1/ GM-Tg-cang-T17758-Ab-2;
GM-Tg-bovg-T17758-Ab-1/ GM-Tg-bovg-T17758-Ab-2; GM-Tg-equg-T17758-Ab-1/ GM-Tg-equg-T17758-Ab-2
Products NameAnti-PLAU monoclonal antibody
Formatmab
Target NamePLAU
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PLAU benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species UROK/ PLAU/ ATF VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMAD000145human PLAU Adenovirus particle
    ORF Viral VectorpGMAD000145human PLAU Adenovirus plasmid
    ORF Viral VectorpGMLPm005320mouse Plau Lentivirus plasmid
    ORF Viral VectorvGMLPm005320mouse Plau Lentivirus particle


    Target information

    Target IDGM-T17758
    Target NamePLAU
    Gene ID5328,18792,25619,705853,403426,101098338,281408,100072886
    Gene Symbol and SynonymsATF,BDPLT5,PLAU,QPD,u-PA,UPA,UPAM,URK
    Uniprot AccessionP00749,P29598,Q05589
    Uniprot Entry NameUROK_HUMAN,UROK_RAT,UROK_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseDent disease
    Gene EnsemblENSG00000122861
    Target ClassificationN/A

    The target: PLAU, gene name: PLAU, also named as ATF, BDPLT5, QPD, UPA, URK, u-PA. This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.